Compare DOLE & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | SANA |
|---|---|---|
| Founded | 1851 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 983.4M |
| IPO Year | 2021 | 2021 |
| Metric | DOLE | SANA |
|---|---|---|
| Price | $14.65 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.83 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $8,974,210,000.00 | N/A |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $1.92 | N/A |
| P/E Ratio | $97.62 | ★ N/A |
| Revenue Growth | ★ 7.09 | N/A |
| 52 Week Low | $12.20 | $1.26 |
| 52 Week High | $15.36 | $7.30 |
| Indicator | DOLE | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 73.63 | 50.42 |
| Support Level | $13.49 | $3.16 |
| Resistance Level | $14.16 | $4.32 |
| Average True Range (ATR) | 0.34 | 0.37 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 96.51 | 72.72 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.